Articles from KORU Medical Systems

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2024.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in Piper Sandler’s 36th Annual Healthcare Conference on December 5, 2024.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will be participating in two upcoming Investor Conferences.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report third quarter 2024 financial results on Wednesday, November 13, 2024. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will be participating in investor meetings at the 8th Annual Lake Street Best Ideas Growth Conference in New York on Thursday, September 12, 2024.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in the Canaccord Genuity 44th Annual Growth Conference on August 14, 2024.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2024 financial results on Wednesday, August 7, 2024. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQKRMD), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, are joining forces to offer a high-volume subcutaneous drug infusion solution. “We want to ensure that medications are safe and easy to use for patients and care providers around the world. By combining KORU Medical’s expertise in pump devices with our expertise in large-volume prefillable polymer syringes, we can help improve the time-to-market of infusion therapies while simplifying the subcutaneous drug infusion of large volume drugs,” says Andreas Reisse, CEO of SCHOTT Pharma. The solution particularly addresses the market for treatments that are administered subcutaneously and require recurring dosing regimens, such as chronic diseases or cancer. The prefillable polymer syringes from SCHOTT Pharma that are used with KORU Medical’s Freedom System are available in large-volume formats from 5mL to 50mL to meet the need for larger infusion volumes and higher drug viscosities.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 1, 2024. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced that the Company will report fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today announced that the Company will participate in Piper Sandler’s 35th Annual Healthcare Conference on November 29, 2023.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today announced that the Company will participate in two upcoming investor conferences.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced that the Company will report third quarter 2023 financial results on Wednesday, November 8, 2023. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced that the Company will participate in the Gilmartin Group Emerging Growth Company Showcase on September 21, 2023.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced that the Company will participate in the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients, today announced that the Company will report second quarter 2023 financial results on Wednesday, August 9, 2023. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today announced that the Company will report first quarter 2023 financial results on Thursday, May 4, 2023. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today announced that the Company will report fourth quarter and full year 2022 financial results on Wednesday, March 8, 2023. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference on December 1st, 2022.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today announced that the Company will participate in two upcoming investor conferences.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report third quarter 2022 financial results on Wednesday, November 9, 2022. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the company will participate in Canaccord Genuity's 42nd Annual Growth Conference on August 10th, 2022.

KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report second quarter 2022 financial results on Wednesday, August 3, 2022. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the first quarter ended March 31, 2022.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced 510k clearance for use of the KORU Medical FreedomEdge® infusion system to deliver pegcetacoplan 20 mL solution, branded as EMPAVELI® or Aspaveli® and commercialized by Apellis in the United States and by Sobi outside the United States.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report first quarter 2022 financial results on Wednesday, May 4, 2022. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced the appointment of Brian Case, a veteran medical technology R&D leader with over 20 years of experience, as the Company’s new Chief Technology Officer. Mr. Case will lead product development and innovation as the Company defines and executes a technology strategy to support a global drug delivery portfolio.

First paragraph, first sentence of release dated February 16, 2022, should read: Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022. [instead of Repro Med Systems, Inc. dba KORU Medical Systems NASDAQ: KRMDNASDAQKRMD)

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report fourth quarter and full year 2021 financial results on Wednesday, March 2, 2021. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced FDA 510(k) clearance that expands on-label use of the FREEDOM60 Infusion System to two additional subcutaneous Ig (SCIg) medications, Cutaquig®, manufactured by Octapharma, and Xembify®, manufactured by Grifols.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced it will host an investor day to provide an update to its strategic plan.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the third quarter ended September 30, 2021.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced 510k clearance for use of the KORU Medical FreedomEdge® infusion pump to deliver Hizentra® [immune globulin subcutaneous (human) 20% liquid] 20 mL prefilled syringes. Hizentra® is the most prescribed subcutaneous Ig product and the first to be available in a prefilled syringe format.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced its participation in two upcoming conferences, Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and the 33rd Annual Piper Sandler Healthcare Conference.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing and commercialization of innovative and easy-to-use home infusion solutions, today announced its collaboration with Gilero, a medical device design and manufacturing company. Gilero offers unparalleled engineering and manufacturing solutions and has been a trusted partner for medical and drug delivery device companies for 20 years. The collaboration is part of KORU Medical’s strategic focus on innovation as the Company expands and evolves its at-home infusion products and portfolio.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced the appointment of two new leaders who will be responsible for key elements of the Company's growth strategy: Rob Cannon as the Company's new Vice President of Sales, and Brian Hertzog as the Company's new Vice President of BioPharma Business Development. Mr. Cannon will be responsible for U.S. sales and increasing the overall penetration of subcutaneous therapy for commercialized biopharmaceutical drugs. Mr. Hertzog will be responsible for leading biopharmaceutical business development and increasing the number of new biopharmaceutical drugs on the Freedom platform.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced that the Company will report third quarter 2021 financial results on Wednesday, November 10, 2021. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced the appointment of Chris Pazdan as the Company's new Vice President of Quality Assurance and Regulatory Affairs. Mr. Pazdan will be responsible for all quality assurance and regulatory affairs as the Company continues to build out a robust Quality Management System and a regulatory strategy to meet evolving global standards.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the second quarter ended June 30, 2021.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced that the Company will participate in Canaccord Genuity’s 41st Annual Growth Conference.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced that the Company will report second quarter 2021 financial results on Wednesday, August 11, 2021. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the first quarter ended March 31, 2021.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQKRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced that the Company will report first quarter 2021 financial results on Wednesday, May 12, 2021. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.